Renaud La Joie

List of Publications by Year
in descending order

134 papers	10,324 citations	41344 49 h-index	39675 94 g-index
144 all docs	144 docs citations	144 times ranked	9684 citing authors

#	Article	IF	Citations
1	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimerâ€™s disease. Brain, 2017, 140, 3286-3300.	7.6	472
2	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	30.7	471
3	The behavioural/dysexecutive variant of Alzheimerâ€™s disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
4	Four distinct trajectories of tau deposition identified in Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 871-881.	30.7	354
5	Prospective longitudinal atrophy in Alzheimerâ€™s disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	12.4	353
6	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	4.2	341
7	Region-Specific Hierarchy between Atrophy, Hypometabolism, and Î²-Amyloid (Aβ) Load in Alzheimer's Disease Dementia. Journal of Neuroscience, 2012, 32, 16265-16273.	3.6	319
8	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	7.6	319
9	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
10	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage: Clinical, 2013, 2, 356-365.	2.7	297
11	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. NeuroImage, 2015, 111, 526-541.	4.2	284
12	Structural imaging of hippocampal subfields in healthy aging and Alzheimerâ€™s disease. Neuroscience, 2015, 309, 29-50.	2.3	265
13	Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. NeuroImage, 2013, 83, 450-457.	4.2	234
14	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	10.2	220
15	Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. NeuroImage: Clinical, 2013, 3, 155-162.	2.7	219
16	Why musical memory can be preserved in advanced Alzheimerâ€™s disease. Brain, 2015, 138, 2438-2450.	7.6	214
17	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	5.3	198
18	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	3.6	196

#	Article	IF	Citations
19	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
20	Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. NeuroImage, 2010, 53, 506-514.	4.2	149
21	Intrinsic Connectivity Identifies the Hippocampus as a Main Crossroad between Alzheimerâ€™s and Semantic Dementia-Targeted Networks. Neuron, 2014, 81, 1417-1428.	8.1	148
22	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
23	Plasma biomarkers of astrocytic and neuronal dysfunction in earlyâ€•and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.8	143
24	Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimer's and Dementia, 2017, 13, 550-560.	0.8	135
25	Alzheimerâ€™s pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	7.6	131
26	Effects of age and Alzheimer's disease on hippocampal subfields. Human Brain Mapping, 2015, 36, 463-474.	3.6	130
27	A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals?. Hippocampus, 2017, 27, 3-11.	1.9	130
28	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
29	Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 10402-10411.	3.6	117
30	Age effect on the default mode network, inner thoughts, and cognitive abilities. Neurobiology of Aging, 2013, 34, 1292-1301.	3.1	114
31	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
32	Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden. Journal of Neuroscience, 2014, 34, 8612-8617.	3.6	107
33	Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S141-S150.	2.6	102
34	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	7.6	100
35	A molecular gradient along the longitudinal axis of the human hippocampus informs large-scale behavioral systems. Nature Communications, 2020, 11, 960.	12.8	100
36	Comorbid neuropathological diagnoses in early versus late-onset Alzheimerâ€™s disease. Brain, 2021, 144, 2186-2198.	7.6	100

#	Article	IF	Citations
37	When Music and Long-Term Memory Interact: Effects of Musical Expertise on Functional and Structural Plasticity in the Hippocampus. PLoS ONE, 2010, 5, e13225.	2.5	99
38	Effect of Off-Target Binding on ¹⁸F-Flortaucipir Variability in Healthy Controls Across the Life Span. Journal of Nuclear Medicine, 2019, 60, 1444-1451.	5.0	96
39	Anosognosia in Alzheimer disease: Disconnection between memory and selfâ€related brain networks. Annals of Neurology, 2015, 78, 477-486.	5.3	84
40	Hippocampal subfield volumetry from structural isotropic 1â€‰mm³<scp>MRI</scp> scans: A note of caution. Human Brain Mapping, 2021, 42, 539-550.	3.6	84
41	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84
42	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
43	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	2.7	73
44	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
45	Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.1	73
46	Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan. Neuropsychology Review, 2014, 24, 290-299.	4.9	67
47	Regional AÎ²-tau interactions promote onset and acceleration of Alzheimerâ€™s disease tau spreading. Neuron, 2022, 110, 1932-1943.e5.	8.1	64
48	Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. Neurobiology of Aging, 2017, 59, 72-79.	3.1	60
49	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	7.6	58
50	The many dimensions of human hippocampal organization and (dys)function. Trends in Neurosciences, 2021, 44, 977-989.	8.6	57
51	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	9.0	54
52	Subjective cognitive decline and Î²-amyloid burden predict cognitive change in healthy elderly. Neurology, 2017, 89, 2002-2009.	1.1	53
53	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	2.7	53
54	The Hippocampus Remains Activated over the Long Term for the Retrieval of Truly Episodic Memories. PLoS ONE, 2012, 7, e43495.	2.5	52

#	Article	IF	Citations
55	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.1	49
56	Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimerâ€™s Disease Stages. Journal of Alzheimer's Disease Reports, 2019, 3, 103-112.	2.2	48
57	Qualitative and quantitative assessment of selfâ€reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and Î²â€amyloid imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 23-34.	2.4	47
58	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimerâ€™s disease. ELife, 0, 11, .	6.0	45
59	Brain properties predict proximity to symptom onset in sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1871-1883.	7.6	43
60	Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. JAMA Neurology, 2020, 77, 517.	9.0	43
61	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	2.6	43
62	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimerâ€™s disease. Brain, 2022, 145, 713-728.	7.6	43
63	Role of hippocampal CA1 atrophy in memory encoding deficits in amnestic Mild Cognitive Impairment. NeuroImage, 2012, 59, 3309-3315.	4.2	42
64	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	6.4	41
65	Dissecting the clinical heterogeneity of early-onset Alzheimerâ€™s disease. Molecular Psychiatry, 2022, 27, 2674-2688.	7.9	40
66	Elevated ¹⁸ F-AV-1451 PET tracer uptake detected in incidental imaging findings. Neurology, 2017, 88, 1095-1097.	1.1	38
67	Morphometric network differences in ageing versus Alzheimerâ€™s disease dementia. Brain, 2020, 143, 635-649.	7.6	37
68	Readiness to change and brain damage in patients with chronic alcoholism. Psychiatry Research - Neuroimaging, 2013, 213, 202-209.	1.8	34
69	Progress update from the hippocampal subfields group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 439-449.	2.4	34
70	Diagnostic Accuracy of Amyloid versus ¹⁸Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	5.3	34
71	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimerâ€™s Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	2.9	34
72	Normalization of CSF pTau measurement by Aî²40 improves its performance as a biomarker of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 97.	6.2	31

#	Article	IF	Citations
73	Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. Neurobiology of Aging, 2018, 63, 140-151.	3.1	30
74	Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimer's Research and Therapy, 2019, 11, 61.	6.2	30
75	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. Neurotherapeutics, 2021, 18, 728-752.	4.4	30
76	Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiology of Aging, 2021, 105, 86-98.	3.1	29
77	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
78	Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia. Human Brain Mapping, 2017, 38, 1791-1800.	3.6	26
79	Distinct Interplay Between Atrophy and Hypometabolism in Alzheimerâ€™s Versus Semantic Dementia. Cerebral Cortex, 2019, 29, 1889-1899.	2.9	24
80	FDG-PET Contributions to the Pathophysiology of Memory Impairment. Neuropsychology Review, 2015, 25, 326-355.	4.9	23
81	Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimerâ€™s disease. Brain, 2022, 145, 4489-4505.	7.6	23
82	Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain, 2022, 145, 2823-2833.	7.6	22
83	Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2155-2164.	6.4	20
84	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology, 2020, 95, e1672-e1685.	1.1	19
85	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	5.9	18
86	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
87	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research and Therapy, 2020, 12, 148.	6.2	17
88	Evaluation of a visual interpretation method for tauâ€PET with ¹⁸ Fâ€flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	2.4	17
89	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	1.9	17
90	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage, 2022, 246, 118775.	4.2	17

#	Article	IF	Citations
91	Are AD-Typical Regions the Convergence Point of Multiple Pathologies?. Frontiers in Aging Neuroscience, 2015, 7, 42.	3.4	16
92	An Opioid-Related Amnestic Syndrome With Persistent Effects on Hippocampal Structure and Function. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 392-396.	1.8	16
93	Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series. Journal of Neurotrauma, 2022, 39, 1195-1213.	3.4	16
94	Superior explicit memory despite severe developmental amnesia: Inâ€depth case study and neural correlates. Hippocampus, 2018, 28, 867-885.	1.9	14
95	Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. JAMA Neurology, 2020, 77, 358.	9.0	14
96	BHAâ€CS: A novel cognitive composite for Alzheimer's disease and related disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12042.	2.4	12
97	Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia. Brain Communications, 2019, 1, fcz027.	3.3	11
98	Detecting Alzheimerâ€™s disease biomarkers with a brief tablet-based cognitive battery: sensitivity to AÎ² and tau PET. Alzheimer's Research and Therapy, 2021, 13, 36.	6.2	10
99	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	6.4	10
100	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.1	10
101	Is there a specific memory signature associated with AÎ²-PET positivity in patients with amnestic mild cognitive impairment?. Neurobiology of Aging, 2019, 77, 94-103.	3.1	9
102	Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior, 2021, 15, 2417-2425.	2.1	9
103	Crossed cerebellar diaschisis on¹⁸F-FDG PET: Frequency across neurodegenerative syndromes and association with¹¹C-PIB and¹⁸F-Flortaucipir. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2329-2343.	4.3	9
104	Sex-related differences in the relationship between Î²-amyloid and cognitive trajectories in older adults.. Neuropsychology, 2020, 34, 835-850.	1.3	9
105	Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia. Neurocase, 2019, 25, 39-47.	0.6	8
106	The Rapid Naming Test: Development and initial validation in typically aging adults. Clinical Neuropsychologist, 2022, 36, 1822-1843.	2.3	7
107	Quantification of amyloid beta and tau PET without a structural MRI. Alzheimer's and Dementia, 2023, 19, 444-455.	0.8	7
108	Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. Journal of Nuclear Medicine, 2022, 63, 830-832.	5.0	7

#	Article	IF	Citations
109	Social Behavior Observer Checklist: Patterns of Spontaneous Behaviors Differentiate Patients With Neurodegenerative Disease From Healthy Older Adults. Frontiers in Neurology, 2021, 12, 683162.	2.4	6
110	Fusiform gyrus phosphoâ€tau is associated with failure of proper name retrieval in aging. Annals of Neurology, 2021, 90, 988-993.	5.3	4
111	Toward a Better Understanding of the Injured Hippocampus: Multimodal Imaging in Functionally Relevant Substructures. Journal of Neuroscience, 2014, 34, 10793-10794.	3.6	3
112	[P2â€“373]: AV1451â€PET CORTICAL UPTAKE AND REGIONAL DISTRIBUTION PREDICT LONGITUDINAL ATROPHY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P769.	0.8	3
113	Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies. Brain Imaging and Behavior, 2020, 14, 336-345.	2.1	3
114	Worth the Wait: Delayed Recall after 1 Week Predicts Cognitive and Medial Temporal Lobe Trajectories in Older Adults. Journal of the International Neuropsychological Society, 2021, 27, 382-388.	1.8	3
115	The development of a valid, reliable, harmonized segmentation protocol for hippocampal subfields and medial temporal lobe cortices: A progress update. Alzheimer's and Dementia, 2020, 16, e046652.	0.8	2
116	IC-02-03: EXISTING THRESHOLDS FOR PIB POSITIVITY ARE TOO HIGH. , 2014, 10, P4-P5.		1
117	O3-10-02: LIFETIME COGNITIVE ACTIVITY, APOLIPOPROTEIN E GENOTYPE, AND BRAIN BETA-AMYLOID. , 2014, 10, P228-P228.		1
118	Imaging Alzheimerâ€™s pathology stage by stage. Nature Aging, 2022, 2, 465-467.	11.6	1
119	IC-P-093: EFFECTS OF AGE AND ALZHEIMER'S DISEASE ON HIPPOCAMPAL SUBFIELDS: COMPARISON BETWEEN MANUAL AND FREESURFER VOLUMETRY. , 2014, 10, P52-P53.		0
120	P1-212: THE USE OF NEUROIMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P380-P381.		0
121	P1-297: EFFECTS OF AGE AND ALZHEIMER'S DISEASE ON HIPPOCAMPAL SUBFIELDS: COMPARISON BETWEEN MANUAL AND FREESURFER VOLUMETRY. , 2014, 10, P420-P420.		0
122	IC-02-02: THE USE OF NEUROIMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P4-P4.		0
123	ICâ€Pâ€149: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships With Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P110.	0.8	0
124	ICIâ€01â€01: What Have We Learned?. Alzheimer's and Dementia, 2016, 12, P12.	0.8	0
125	P2â€343: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships with Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P774.	0.8	0
126	[P1â€“031]: DOES APOEâ€Îµ4 HAVE AN AÎ²â€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P245.	0.8	0

#	Article	IF	Citations
127	[ICâ€Pâ€059]: DOES APOEâ€Îµ4 HAVE AN AÎ²â€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P48.	0.8	0
128	[ICâ€Pâ€186]: AV1451â€PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SIDES OF THE SAME COIN?. Alzheimer's and Dementia, 2017, 13, P137.	0.8	0
129	[ICâ€01â€“01]: AV1451â€PET CORTICAL UPTAKE AND REGIONAL DISTRIBUTION PREDICTS LONGITUDINAL ATROPHY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1.	0.8	0
130	[P1â€“414]: DOES APOE Îµ4 HAVE AN AÎ²â€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P435.	0.8	0
131	[O3â€“03â€“04]: AV1451â€PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SIDES OF THE SAME COIN?. Alzheimer's and Dementia, 2017, 13, P904.	0.8	0
132	F1â€01â€02: NONâ€AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE, EARLY AGE OF ONSET AND APOE GENOTYPE ARE ASSOCIATED WITH TAUâ€, NOT AÎ²â€PET. Alzheimer's and Dementia, 2018, 14, P199.	0.8	0
133	ICâ€Pâ€145: NONâ€AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE, EARLY AGE OF ONSET AND APOE GENOTYPE ARE ASSOCIATED WITH TAU, NOT AÎ²â€PET. Alzheimer's and Dementia, 2018, 14, P123.	0.8	0
134	How â€˜atypicalâ€™ is the neuroimaging signature of Alzheimerâ€™s atypical variants? MRI and PET imaging of posterior cortical atrophy and logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e040623.	0.8	0